SCHEMBL31172601

SCHEMBL31172601

COc1cc(C(=O)Oc2c(F)c(F)c(F)c(F)c2F)cnc1Cn1cccn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.37
▸ GAA P10253 2/20 0.37
▸ USP2 O75604 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ KAT7 O95251 6/20 0.36
▸ KAT6A Q92794 6/20 0.36
▸ KAT6B Q8WYB5 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ KAT5 Q92993 1/20 0.35
▸ KAT8 Q9H7Z6 1/20 0.35
▸ KLKB1 P03952 2/20 0.35
▸ KDM4E B2RXH2 3/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ CYP1A2 P05177 2/20 0.34
▸ CYP2C19 P33261 2/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31172651 0.88 LMNA (0.42) HTTGAAUSP2MAPTKAT7
SCHEMBL31172566 0.84 HTT (0.49) HTTGAAUSP2MAPTLMNA
SCHEMBL31172672 0.81 KAT7 (0.42) HTTGAAUSP2MAPTKAT7
SCHEMBL31172554 0.76 KAT7 (0.42) HTTGAAUSP2MAPTKAT7
SCHEMBL31172777 0.74 KAT7 (0.41) HTTGAAUSP2MAPTKAT7
SCHEMBL31172614 0.74 KAT6A (0.47) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31172694 0.72 KLKB1 (0.38) HTTGAAKAT7KAT6AKAT6B
SCHEMBL31172644 0.72 KAT7 (0.42) HTTGAAMAPTKAT7KAT6A
SCHEMBL31172565 0.72 KAT7 (0.40) HTTGAAUSP2MAPTKAT7
SCHEMBL553315 0.68 KLKB1 (0.47) HTTGAAUSP2MAPTKAT7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 — — EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed
WO-2024189598-A2 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. (US) 2024-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B HTT 508/4885GAA 549/4885USP2 749/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B HTT 508/4885GAA 549/4885USP2 749/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B HTT 1323/4885GAA 1771/4885USP2 1322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback